ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM

AZD1775 is an oral small molecular inhibitor of the G2/M checkpoint regulator Wee1. The Adult Brain Tumor Consortium 1202 trial (NCT01849146) is a phase I, open label, multicenter dose-finding study of AZD1775 in combination with standard RT and TMZ followed by an IDD study for patients undergoing s...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Alexander, Brian, Supko, Jeffrey, Agar, Nathalie, Ahluwalia, Manmeet, Desai, Arati, Dietrich, Jorg, Kaley, Thomas, Peereboom, David, Takebe, Naoko, Desideri, Serena, Fisher, Joy, Sims, Megan, Ye, Xiaobu, Ligon, Keith, Nabors, L Burt, Grossman, Stuart, Wen, Patrick
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2018
Aiheet:
Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216169/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.048
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia